TUL erhält Zulassung für klinische Studie mit UBT251-Injektion bei OSA in China
I'm PortAI, I can summarize articles.
The United Laboratories International Holdings Ltd. announced that the China National Medical Products Administration approved a clinical study for UBT251 Injection, aimed at treating moderate to severe obstructive sleep apnea with obesity. This approval was granted on February 2, 2026, and UBT251 Injection is developed by United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the company.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments